CNX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CNX is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act without waiting for a better entry. The stock has some short-term technical support and mildly positive momentum, but the overall setup is mixed: analysts are mostly cautious to bearish, hedge funds are selling, there is no recent news catalyst, and options sentiment is not strongly bullish enough to override those negatives. I would not call it a good buy today; the better call is to hold off or wait for a clearer pullback or fundamental catalyst.
CNX is showing a modestly constructive short-term trend but not a decisive breakout. The MACD histogram is positive and expanding, which supports near-term momentum. RSI_6 at 57.6 is neutral-to-slightly bullish, so the stock is not overbought. Moving averages are converging, suggesting the trend is still undecided rather than strongly directional. Price at 33.84 is sitting just above pivot support at 33.61, with near resistance at 34.50 and 35.05. The short-term pattern data suggests a small upside bias over the next day/week, but a weaker month view, so the technical picture is mixed rather than a clean entry signal.
["MACD histogram is positive and expanding, signaling improving momentum.", "Options flow is bullish, with low put-call ratios on both open interest and volume.", "Stock trend estimate points to a modest upside over the next day and week."]
["No news catalysts in the past week.", "Hedge funds are selling, with selling increasing sharply over the last quarter.", "Analysts have been trimming price targets and several firms keep Underweight/Underperform ratings.", "The expected one-month stock trend is negative.", "No recent insider or congressional buying support is visible."]
No usable latest-quarter financial snapshot was provided, so there is no reliable quarter-by-quarter revenue or earnings update to assess. Because of that, I cannot confirm recent growth trends from the supplied financial data.
Analyst sentiment has recently turned more cautious. Morgan Stanley cut its target to $32 and kept Underweight, BofA cut to $34 and kept Underperform, and Barclays reduced its target to $35 while staying Underweight. Mizuho is less negative with a Neutral rating and a $42 target, but it also lowered its target. Overall, Wall Street pros are leaning bearish to neutral, with more downside caution than upside conviction.
